Toboroz
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
NCT07018869· 3. fázis· SWOG Cancer Research Network· Forrás
Contact: Leandro P. Moraes (principal investigator)
Toboroz
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926· 3. fázis· NRG Oncology· Forrás
Contact: Director Regulatory Affairs
Toboroz
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT05812807· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Janine Harewood (principal investigator)
Toboroz
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
NCT05677490· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Leandro P. Moraes (principal investigator)
Toboroz
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT05334069· Alliance for Clinical Trials in Oncology· Forrás
Contact: Leandro P. Moraes (principal investigator)
Toboroz
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
NCT05040360· 2. fázis· SWOG Cancer Research Network· Forrás
Contact: Paul M. Bloomston (principal investigator)
Fut, nem toboroz
Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer
NCT04559139· 2/3. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Fut, nem toboroz
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
NCT04340141· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Fut, nem toboroz
Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread
NCT04233866· 2. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Toboroz
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
NCT04239573· ECOG-ACRIN Cancer Research Group· Forrás
Contact: Paul M. Bloomston (principal investigator)
Toboroz
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
NCT04267848· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Leandro P. Moraes (principal investigator)
Fut, nem toboroz
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer
NCT04214067· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT04095364· 3. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
NCT03907488· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
NCT04071457· 3. fázis· SWOG Cancer Research Network· Forrás
Fut, nem toboroz
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
NCT03811002· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer
NCT03939481· SWOG Cancer Research Network· Forrás
Fut, nem toboroz
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
NCT03375320· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial
NCT03371719· 2. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
NCT02997228· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
NCT02912559· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NCT02488967· 3. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992· 3. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Fut, nem toboroz
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
NCT02193282· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
NCT02194738· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
NCT01896999· 1/2. fázis· National Cancer Institute (NCI)· Forrás